Table 1 Characteristics of patients with PsA and at least one swollen joint at start of first TNFi, pooled across all countries
|  | All patients starting TNFi (TNFi monotherapy and TNFi added to methotrexate) N = 1729 | Subgroup of patients starting TNFi as monotherapy N = 406 | ||
|---|---|---|---|---|
N | Â | N | Â | |
Female sex, N (%) | 1729 | 799 (53.8) | 406 | 210 (51.7) |
Age, years | 1729 | 49.4 (12.1) | 406 | 49.8 (11.8) |
Symptom duration, years | 1409 | 9.0 (8.6) | 352 | 9.8 (9.1) |
CRP, mg/l | 1645 | 15.0 (21.5) | 376 | 13.6 (17.3) |
DAS28-CRP | 1476 | 4.7 (1.0) | 312 | 4.6 (1.0) |
Physician global score | 1602 | 4.9 (2.3) | 370 | 5.2 (2.1) |
Patient global score | 1559 | 6.6 (2.3) | 339 | 6.6 (2.2) |
Use of methotrexate, N (%) | 1729 | 1323 (76.5) | 406 | 0 (0.0) |
Details regarding peripheral arthritis | 1729 | Â | 406 | Â |
Tender joints (28 joints count) | Â | 7.4 (6.0) | Â | 7.0 (5.9) |
Swollen joints (28 joints count) | Â | 4.9 (4.1) | Â | 4.9 (4.1) |
Number of joints involved, N (%) | ||||
 • < 5 (out of 28) |  | 1043 (60.3) |  | 246 (60.6) |
 • ≥ 5 (out of 28) |  | 686 (39.7) |  | 160 (39.4) |
Type of joints involved, N (%) | ||||
 • Only small joints |  | 1034 (59.8) |  | 255 (62.8) |
 • Only large joints |  | 210 (12.1) |  | 42 (10.3) |
 • Small and large joints |  | 485 (28.1) |  | 109 (26.8) |